Sodium-glucose cotransporter 2 (SGLT2) inhibitors were originally developed to treat type 2 diabetes by promoting glycosuria through inhibition of renal glucose reabsorption. However, their clinical utility has expanded rapidly following the demonstration of c... ...

请注册登录后继续浏览